After graduating from Yale and Harvard Business School, Linda moved into equity investment management, working at private hedge funds — including Essex Investment Management and Tudor Investment Corporation – – and earning her Chartered Financial Analyst (CFA) designation.
Increasingly focused on the life sciences, Linda worked as a healthcare research analyst for Banc of America Securities. The lure of sequencing the human genome took Linda to Applied Biosystems, where she started an M&A group and help sell the company to Life Technologies. Since then, Linda has worked in corporate development and finance roles at global- and venture-backed life science companies, including VitaPath Genetics, Novartis Diagnostics, Singulex, and Raindance (sold to Bio-Rad).
After a breakthrough investment in nVision, which was later sold to Boston Scientific for up to $275 million, Linda and her HBS classmate, Corinne Nevinny, founded Avestria Ventures, which invests in early-stage women’s health or female-founded life science companies.
Linda is attending / has attended: